Treatment effect of topical fluconazole nanoparticles on Tinea versicolor
Phase 2
- Conditions
- Tinea versicolor.Pityriasis versicolorB36.0
- Registration Number
- IRCT20120707010203N10
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Clinical feature of Tinea versicolor
Positive Smear test
Exclusion Criteria
Liver disease
Nephrotic disorders
Diabetes
Malignant disease
Pregnancy
Breast feeding
anti-fungal treatment in recent one months
Sore or damage in infected area
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Skin lesion area. Timepoint: At the beginning of study (time zero) and 2, 4 and 8 weeks after treatment. Method of measurement: Clinical evaluation and smear test.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fluconazole-NLC nano emulgel's antifungal activity against Malassezia species in Tinea versicolor?
How does fluconazole-NLC nano emulgel (0.5%) in IRCT20120707010203N10 compare to clotrimazole cream for Tinea versicolor efficacy and safety?
Which biomarkers predict response to fluconazole-NLC nano emulgel in Tinea versicolor patients with varying Malassezia strain susceptibility?
What are the safety profiles and adverse event management strategies for fluconazole-NLC nano emulgel versus clotrimazole cream in Tinea versicolor treatment?
Are there synergistic effects of combining fluconazole-NLC nano emulgel with other azole antifungals for Tinea versicolor (B36.0) management?